Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.35 |
| ▸ | CA4 | P22748 | 3/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28703625 | 0.97 | CES2 (0.40) | CES2CES1ENPP2CA4CA6 | |
| SCHEMBL15649887 | 0.85 | ENPP2 (0.33) | CES2CES1ENPP2CA6CA5A | |
| SCHEMBL16374001 | 0.83 | TTR (0.41) | CES2CES1ENPP2 | |
| SCHEMBL16384322 | 0.83 | CA2 (0.36) | CES2CES1CA2 | |
| SCHEMBL9939130 | 0.83 | ALDH1A1 (0.35) | CES2CES1ENPP2KDM4EALDH1A1 | |
| SCHEMBL1804144 | 0.82 | ORAI1 (0.43) | CES2CES1CA4CA1CA2 | |
| SCHEMBL1277215 | 0.80 | ERN1 (0.38) | ENPP2CA4CA6CA5ACA7 | |
| SCHEMBL28824846 | 0.80 | ENPP2 (0.33) | ENPP2CA4CA6CA5ACA7 | |
| SCHEMBL18090905 | 0.79 | ERN1 (0.39) | CES2CES1CA4CA1CA2 | |
| SCHEMBL28736451 | 0.79 | MGLL (0.39) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119591560-B | Synthesis method of thifluzamide | 湖南速博生物技术有限公司 | 2025-04-29 | — | — | CN | claimed |
| WO-2025074340-A1 | A PROCESS FOR PREPARATION OF AMINOBIPHENYL COMPOUNDS AND INTERMEDIATES THEREOF | UPL LIMITED (IN) | 2025-04-10 | — | — | WO | claimed |
| CN-119591560-A | Synthesis method of thifluzamide | 湖南速博生物技术有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-119504448-A | Synthesis method of 3',4',5' -trifluoro-2-aminobiphenyl | 河北八亿时空药业有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119236835-B | Continuous reaction system and continuous method for producing 3',4',5' -trifluoro-biphenyl-2-amine | 天津凯莱英医药科技发展有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-116217354-B | Efficient green synthesis method and product of liquid crystal monomer | 烟台德润液晶材料有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-119236835-A | Continuous reaction system and continuous method for producing 3',4',5' -trifluoro-biphenyl-2-amine | 天津凯莱英医药科技发展有限公司 | 2025-01-03 | — | — | CN | claimed |
| WO-2025006693-A1 | CANNABIDIOL-LIKE COMPOUNDS AND METHODS FOR THE SELECTIVE PREPARATION OF THE SAME | UNIVERSITY OF MISSISSIPPI (US) | 2025-01-02 | — | — | WO | claimed |
| CN-119019319-A | Synthesis method of N, N' -bis 2, 6-tetramethyl-4-piperidinyl-1, 3-phthalamide | 浙江诺驷新材料科技有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-118307475-B | Preparation method of stable isotope labeled fluxapyroxad internal standard reagent | 谱同生物医药科技(常州)有限公司 | 2024-11-22 | — | — | CN | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2107067-A1 | Boron catalysed peptide synthesis | DSM IP Assets B.V. (NL) | 2009-10-07 | — | — | EP | claimed |
| EP-2081946-A2 | ADENOSINE DERIVATIVES FOR THE TREATMENT OF PAIN | Biovitrum AB (publ) (SE) | 2009-07-29 | — | — | EP | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| WO-2008000745-A2 | ADENOSINE DERIVATIVES FOR THE TREATMENT OF PAIN | BIOVITRUM AB (PUBL) (SE) | 2008-01-03 | — | — | WO | claimed |
| US-7037905-B2 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2006-05-02 | — | — | US | claimed |
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2004-03-18 | — | — | US | claimed |
| WO-2003105860-A1 | PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | claimed |
| EP-1277755-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT WITH AXIAL ASYMMETRY, PROCESS FOR PRODUCING THE SAME, AND APPLICATION TO ASYMMETRIC SYNTHESIS OF $g(a)-AMINO ACID DERIVATIVE | Nagase & Co., Ltd. (JP) | 2003-01-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | LIPE, CEL, LIPA | CES2 18/4885CES1 9/4885ENPP2 998/4885 |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | CES2 1317/4885CES1 1971/4885ENPP2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.